Descriptive Analysis of G-CSF Use in Patients With Breast Cancer, Lung Cancer, or Lymphoma Treated
Status:
Completed
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
Purpose:
With the existing recombinant human granulocyte colony-stimulating factors (G-CSFs) patents
expiring and the FDA approval of new biosimilar and innovator biologics, patients being
treated with Grade III and IV myelosuppressive chemotherapy regimens will have additional
therapeutic options. This observational study will describe the patient characteristics of
new users of G-CSFs. It will describe in the treatment cohorts a primary outcome of
hospitalizations for febrile neutropenia. The BBCIC will use the findings from this
descriptive analysis to design a comparative study evaluating the real-world effectiveness
and safety of biosimilar and innovator G-CSFs.
Aetna, Inc. Amgen College of Pharmacy, University of Nebraska College College of Pharmacy, University of New England Harvard Pilgrim Health Care HealthPartners Institute Henry Ford Health System Momenta Pharmaceuticals, Inc.